UMHAT "Medica Ruse" OOD
- Address
- lock Available on a paid plan
UMHAT Medica Ruse OOD - Pain Management Research
UMHAT Medica Ruse OOD is a medical research facility specializing in clinical investigations of innovative pain management therapies. The center focuses on evaluating novel pharmaceutical delivery systems and analgesic approaches for acute pain conditions, with particular emphasis on postoperative pain relief following surgical procedures.
- Postoperative pain management and analgesic efficacy studies
- Novel drug delivery systems including intranasal formulations
- Orthopedic surgery pain models and nociceptor-mediated pain research
The research center conducts multi-center comparative trials examining advanced pain relief modalities, including assessment of fentanyl nasal spray formulations versus placebo controls. Their clinical investigations utilize orthopedic surgery pain models to evaluate analgesic effectiveness, with research findings applicable to broader postoperative pain scenarios including visceral pain management. This approach enables the center to contribute valuable evidence for bridging analgesic effectiveness across different pain etiologies and surgical contexts.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 6 therapeutic areas and 15 of 35 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Immunic AG1active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Immunic AG2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in UMHAT "Medica Ruse" OOD
lock Showing 1 of 15 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Multi-Center Study Comparing Fentanyl Citrate Nasal Spray and Placebo for Postoperative Pain Management in Orthopedic Surgery Patients | 5med GmbH, CCDRD Cooperative Clinical Drug Research and Development AG | Phase III | Not Recruiting | Apr 2024 | Oct 2025 |
IMP list
lock Showing 1 of 35 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Vidofludimus Calcium | 2 | Unknown | 2021-12-20 | 2022-03-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.